

DETERMINATION OF CD4+ CELL COUNT AND VIRAL LOAD IN HIV-POSITIVE PATIENTS AS POSSIBLE INDICATORS OF ART EFFECTIVENESS

Kriti Gupta, Pooja Sharma, Radha Chauhan, Mohd. Shariq

Mahatma Vidur Autonomous State Medical College

Background

Human immunodeficiency virus (HIV) epidemic has emerged as amongst the greatest threats to human health. Fighting the epidemic involves policies that reduce the new infections and increase the survival rates of those already infected. In recent time, highly active antiretroviral therapy (HAART) has become accessible to the patients [1]. The benefits of combined antiretroviral therapy are well acknowledged in literature [2,3]. The initiation of antiretroviral therapy (ART) among patients suppresses HIV replication and recovers CD4+ cell count [4, 5].

The global response to end Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) by 2030 is crucially reliant on effective viral load (VL) monitoring and management [6, 7]. A strong predictor of the development to AIDS is the CD4+ T-cell (CD4+) count reported as an absolute level or count of cells (expressed as cells per cubic millimetre of blood) [8]. Soon after starting ART, there is a rapid increase in the peripheral CD4+ cell count [9–11]. Thus, CD4+ cell count recovery after initiation of ART is a potential marker of HIV patient's clinical outcome and an increase in CD4+ cell count indicates a favourable outcome related with both AIDS and non-AIDS-related conditions and the improvement in life expectancy [10–13]. Changes in CD4+ count constitute an important component in patient monitoring and assessment of response to treatment particularly for patients who do not have access to routine viral load testing. As per WHO recommendations CD4+ count monitoring is required every 6 months and viral load testing only when the capacity exists [14]. However, the measurements of CD4+ in most developing countries is not done on a customary basis.

Revision of WHO guidelines in 2010 incorporated some modifications in the management of HIV infected patients. Among them was use of less toxic antiretroviral drugs in first line [1]. In addition, the treatment was to be given to all patients unlike the earlier guidelines wherein the treatment was given only to patients with a CD4+ count <350cells/mm³. The victory of HAART however significantly depends on standard patient follow-up to the treatment during their lifetime. Previous studies have documented rise of CD4+ cell count of at least 25–50 cells/mm³ during the first 12 months on ART, to be correlated with improved clinical outcomes, even in the presence of detectable viremia and recommended that monitoring CD4+ cell count recovery presents an early chance to recognize patients at risk of poorer prognosis [11,15, 16].

Although most patients attain CD4+ cell count recovery after effective ART, a considerable proportion of up to 45% do not experience an appropriate increase in their CD4+ cell counts [4,17, 18]. Patients on ART with poor CD4+ cell count recovery, as defined by either an insufficient increase in CD4+ cell counts from baseline (e.g., < 50 or < 100 cells/mm³) or a failure to achieve a CD4+ cell count over specific thresholds (e.g., 200, 350 or 500 cells/mm³), are at bigger risk of AIDS and serious non-AIDS morbidity and mortality [15, 12–16]. The risk of these combined outcomes in association with a poor CD4+ recovery are greater when ART was initiated at lower CD4+ cell counts [14, 17]. Numerous contributing factors are responsible for poor CD4+ cell count recovery after ART initiation, which include age at the start of therapy, gender, WHO clinical disease stage, duration of untreated HIV infection, viral hepatitis co-infection, baseline CD4+ cell counts, and specific ART regimens [12, 19–23]. Genetic and environmental factors have also been correlated to poor CD4+ cell count recovery during ART, even after adjustment for factors known to influence CD4+ cell count rise [19, 24–26]. Even with existing facts that HIV-infected patients in Africa show least CD4+ cell count recovery as compared with other regions—large enough to potentially influence clinical outcomes [26, 27]; data on CD4+ cell count recovery following initiation of ART are still limited in Sub-Saharan Africa where most patients initiate ART at advanced stages of disease [28, 29].

One major question is whether treatment can be delayed without irreversible immune system damage [30–33], as might be suggested if CD4+ counts normalize irrespective of the pre-treatment CD4+ count. Another significant topic of concern is whether the beneficial effects of ART in raising CD4+ counts are maintained long-term, or are for a limited duration of time and CD4+ counts eventually stabilize or decline in patients on ART. There are contradictory reports about the pattern of CD4+ counts after multiple years of ART.

Studies of North American and European adults have concluded that CD4+ count continue to rise after 4 to 7 or more years of treatment [34–38] or that the CD4+ count stabilizes, overall [28,29] or in a subset of patients [38,39,40]. Most analyses have constrained CD4+ count assessment to times when plasma HIV-1 RNA (vRNA) was suppressed, e.g. to <50 copies/ml. The characteristics of patients who remain virologically suppressed are likely different from those who are not, resulting in potential selection biases. Therefore it is necessary to estimate CD4+ trajectories in entire populations initiating ART. Additional biases may happen if drop-out, often common, is ignored. For example, if more immunocompromised patients with lower CD4+ counts drop out more often, an analysis that simply includes the patients in follow-up will overestimate the CD4+ count trajectory in the entire population. Such issues may explain why different studies reach diverse conclusions regarding long-term CD4+ count trajectories.

Early initiation of antiretroviral therapy (ART) is vital for suppressing viral replication, enhancing immune function, and reducing morbidity and mortality rates [41]. Viral suppression is defined as having a VL of fewer than 1000 copies/mL after a minimum of six months on ART [42]. The Joint United Nations Programme on HIV/AIDS (UNAIDS) 95:95:95 target aims to identify 95% of persons living with HIV (PLHIV), initiate 95% of those identified on ART, and ensure that 95% of those initiated on ART are virally suppressed by 2030 [43, 44]. This approach not only benefits individual patients but also reduces HIV transmission at the population level [42].

Sub-Saharan Africa (SSA) has made noteworthy progress by shifting from CD4+ cell count monitoring to VL monitoring, reflecting a more effective approach for managing HIV [45]. The availability of potent ART has revolutionised HIV care, leading to improved patient outcomes and sustained viral suppression [46]. However, challenges such as viral rebound and suboptimal suppression rates among specific demographic groups, particularly adolescents, continue to hinder effective HIV management [47, 48].

Aim: To compare CD4+ cell count and viral load before and after initiation of antiretroviral therapy in HIV-positive patients.

Methods

A retrospective, observational cohort study by reviewing the documents was conducted among HIV-infected patients initiating first-line ART at the HIV care and treatment clinic between January 2015 and February 2025. Document review was done for comparison of baseline CD4 and CD4 after initiation of ART. Viral load before and after initiation of ART was also compared. Patients were included in this study if they received their initial first-line combination ART regimen for at least 12 months, had complete information about baseline covariates, and had CD4+ cell count and viral load results available at baseline before and 12 months after the initiation of ART. Patients with missing data for essential variables were excluded from the study analysis. Median values of baseline and latest CD4 were calculated and compared. Data analysis was done using SPSS version 23 (SPSS, Inc., Chicago, IL, USA) software.

Written informed consent from patients was not required since this retrospective study only used routinely collected data, but patient records/information were anonymized and only code numbers were used throughout the study.

CD4+ cell counts are performed at baseline and every six months during follow up. CD4+ cell count results recorded at the baseline prior to and 12 months after the initiation of ART were taken for analysis in this study. CD4+ cell count was categorized into three categories, that is, less than 200, 200–500, 500-1500 and more than 1500 cells/mm³. Viral Load was distributed in the range <20 (TND), 20-50, 50-1000, 1000-10000, >10000, >100000 copies/ml.

Among 1008 HIV positive patients majority (80.4%) belonged to age group 21-50 years followed by 51-70 years (10.4%). Male comprised 62.9% of the patients coming to the ARTc for treatment followed by females (36.8%). Three (0.3%) patients were transgender.

Results

Following tables (Tables 1-3) show status of patients and comparison of CD4+ count and viral load before and after the initiation of ART.

Table 1: Status of patients

Status	No. of patients in % (n=1008)
Living on ART	60.2%
Died	18.8%
Loss of follow-up	7.7%
Opted-out	3.4%
Transfer-out	6.6%
Unknown status	3.1%

Table 2: Comparison of percentage of patients with CD4+ count in the specified range before and after initiation of ART.

CD4+ count range (cells/mm ³)	% of patients with baseline CD4+ count(n=1008)	% of patients with latest CD4 count (after initiation of ART) (n=1008)
>1500	0.7%	0.79%
500-1500	19.1%	38.6%
200-500	39.2%	35.01%
<200	34.3%	19.1%
Unknown	6.54%	0.59%

Median of base line CD4 count was calculated to be 289 cells/mm³ which increased to 458 cells/mm³ after initiation of ART.

Table 3. Comparison of % of patients with viral load in specified range before and after initiation of ART.

Viral Load (copies/ml)	% of patients with baseline viral load (n=1008)	% of patients with latest viral load (after initiation of ART) (n=1008)
TND (<20)	20.5%	53.4%
20-50	8.1%	1.1%
Low (50-1000)	6.8%	4.5%
Moderate (1000-10000)	3.2%	0.7%
High (>10000)	3.3%	1.2
Very high (>100000)	2.3%	1.9%
Unknown	55.7%	37%

Maximum percentage of patients showed viral load suppression in patients with moderate viral load range (between 1000-10000) decreasing from 3.2% to 0.7%.

Percentage of patients showing undetectable target raised from 20.5% to 53.4%.

Discussion

Analysis of CD4+ count is an important component in monitoring and evaluating progression of HIV in resource limited settings. The median baseline CD4+ cell count of this study (289 cells/mm³) was similar to some of the studies, which reported median CD4+ cell counts of 240 cells/mm³ [49] and 257 cells/mm³ [50] at ART initiation. This was, however, higher than the median baseline CD4+ cell counts reported in some African studies, including 152 and 201 cells/mm³ in Northern Ethiopia [51, 52], 144 cells/mm³ in Northwest Ethiopia [53], 142 cells/mm³ in Nigeria [54] and 147 cells/mm³ in six sub-Saharan African countries [55]. At 12 months after starting ART, the median CD4+ cell count increased to 458 cells/mm³ (an increase of +169 cells/mm³ from baseline) and the proportion of patients with CD4+ cell counts < 200 cells/mm³ decreased from 34.3% to 19.1%. This supports data from other studies that ART can lead to an increase in CD4+ cell counts and a decrease in the proportion of patients with severe immunosuppression [39, 52, 53, 54]. In a study from the Ethiopian HIV cohort [52], the median CD4+ count after ART increased from 201 to 423 cells/mm³, and the proportion of patients with CD4+ count < 200 cells/mm³ decreased from 49.6 to 15.6%. In another Ethiopian HIV cohort study [53], the median CD4+ cell count increased from 144 cells/mm³ at baseline to 266 cells/mm³ at 12 months, and the proportion of patients with CD4+ count < 100 cells/mm³ decreased from 31 to 6%. In the South African HIV cohort study [56], the median CD4+ cell count increased from 97 to 261 cells/mm³ at 48 weeks and the proportion of patients with CD4+ count < 100 cells/mm³ decrease from 51 to 4%. In this study, the increase in CD4+ cell count varied according to baseline CD4+ counts and was larger in patients with low counts compared to those with high counts. Our results are similar to reports from other studies, indicating that a low baseline CD4+ count does not preclude an excellent CD4+ cell count response to ART [56]. This finding is clinically important, because a higher CD4+ cell count is associated with the greatest benefit for patients on ART with a low CD4+ count [9]. About 39.4% of our patients reached a CD4+ cell count >500 cells/mm³ at 12 months of ART. Of note, patients who regain their CD4+ cell count to this immunological point have a better clinical outcome with both HIV- and non-HIV-related morbidity and mortality [20, 22]. Studies from other parts of the country have estimated that 37.6% [57] and 38.8% [52] of patients had reached CD4+ cell counts >500 cells/mm³ after ART start. Recently, one Ethiopian HIV cohort study reported 39% of patients reached a CD4+ cell count >500 cells/mm³ at 12 months [50]. The South African HIV cohort study reported 6.8% of patients achieved a CD4+ cell count >500 cells/mm³ at 48 weeks [56]. Nearly 59% of our patients initiated ART with CD4+ counts >200 cells/mm³ and 39.4% achieved a CD4+ cell count >500 cells/mm³. Studies have reported that individuals initiating ART at higher counts have their CD4+ cell count return to nearly normal or normal (>500 cells/mm³) than those who initiated at lower counts (< 200 cells/mm³) [39, 51]. These findings supplement the evidence suggesting that, to facilitate immune recovery, ART should be started before CD4+ count has fallen below 200 cells/mm³. Studies propose that CD4+ cell count recovery after ART depends predominantly on the baseline levels with patients starting with low CD4+ counts failing to recover CD4+ cell count to >500 cells/mm³ [58]. In the Italian HIV cohort study, having baseline CD4+ count < 350 cells/mm³ was associated with poor CD4+ cell count recovery to >500/mm³ [59]. The Johns Hopkins HIV cohort study reported that delaying to initiate ART at low CD4+ count (< 350 cells/mm³) was associated with failure to recover CD4+ cell count to >500/mm³ [60]. The FHDH HIV cohort study reported that a higher CD4+ count at ART initiation was strongly associated with a higher probability of CD4+ cell count recovery to >500 cells/mm³ [61]. Other studies even reported that recovery to CD4+ cell count >500 cells/mm³ may be achievable only in patients starting with counts >350 cells/mm³ [62]. These results support current guidelines to start ART in all patients before they reach a critical CD4+ cell count and suggest that there may be immunological benefits associated with initiating therapy at even higher CD4+ counts. Patients who started ART at lower CD4 counts continued to have lower CD4 counts than those who began ART at higher CD4 counts.

In the present study, percentage of patients showing undetectable target raised from 20.5% to 53.4%. According to the WHO [21], PLHIV with an undetectable VL cannot transmit HIV to their partners during sexual intercourse. Additionally, pregnant women with undetectable VL are at low risk of transmitting HIV to their children

during childbirth or breastfeeding. While early ART may be one of the most promising strategies to reduce HIV incidence, the extent to which rapid suppression of virus influence subsequent HIV transmission in the early phases after HIV diagnosis remains unknown, as diagnosis of HIV infection is often associated with at least transiently reduced risk behaviours and a decreased risk of HIV transmission even in the absence of ART.

This study has some limitations. First, recommended ART regimens have changed during recent years, so CD4+ outcomes might be different for patients who are starting ART now. As current regimens tend to be better tolerated and possibly more efficacious, in part because of simpler dosing (e.g. once daily) leading to improved adherence, patients starting ART now might have better CD4+ count outcomes than in our study.

Third, it is possible that the better outcomes among patients starting ART at higher CD4+ counts are attributable to differences in other patient characteristics. For example, it is possible that starting ART at higher CD4+ counts is associated with health-seeking behaviour, so patients starting ART at higher CD4+ counts might be expected to fare better for this reason. The major limitation of the study is that the study methodology involved a review of records; therefore, the analysis and interpretation of the data are limited to only those variables that are routinely collected from patients and captured in patient records. Some variables, such as patients' clinical condition, which could have played a major role in initial VL testing and VL suppression, were not available. A baseline VL count was not available for some of the clients; hence, analysis of the baseline VL could not be performed for those patients. Since the study did not measure these other variables, the study was unable to account for the influence of these factors in the analysis.

Conclusion

In conclusion, CD4+ cell count failed to recover in a substantial proportion of patients initiating ART in this resource-limited setting. Therefore, novel therapeutic approaches, with good access to CD4+ cell count monitoring and a focus on those at greatest risk, are needed to maximize CD4+ cell count recovery and improve outcomes during therapy. VL suppression was low among the patients. Health promotion activities are needed for people who have been suppressed to maintain and achieve a lifetime undetectable VL, targeting the younger age group.

Determination of CD4+ cell count and Viral Load in HIV-positive patients as possible indicators of ART effectiveness

Kriti Gupta, Pooja Sharma, Radha Chauhan, Mohd. Shariq

Mahatma Vidur Autonomous State Medical College

The introduction of antiretroviral therapy (ART) among patients formerly naïve to treatment leads to suppression of HIV replication and CD4+ cell count recovery. The global response to end Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) by 2030 is critically dependent on effective viral load (VL) monitoring and management cluster of differentiation 4 (CD4+) cell count recovery after initiation of ART is a potential indicator of HIV patient's clinical outcome and an increase in CD4+ cell count indicates a favourable outcome related with both AIDS and non-AIDS-related conditions and the improvement in life expectancy. Early initiation of antiretroviral therapy (ART) is essential for suppressing viral replication, enhancing immune function, and reducing morbidity and mortality rates. In conclusion, CD4+ cell count failed to recover in a substantial proportion of patients initiating ART in this resource-limited setting. Therefore, novel therapeutic approaches, with good access to CD4+ cell count monitoring and a focus on those at greatest risk, are needed to maximize CD4+ cell count recovery and improve outcomes during therapy. VL suppression was low among the patients. Health promotion activities are needed for people who have been suppressed to maintain and achieve a lifetime undetectable VL, targeting the younger age group.

References:

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach—2010 revision. Geneva: World Health Organization; 2010. Available from: <https://www.who.int/publications/i/item/9789241599764>.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. *Lancet*. 2003;362(9377):22-9. doi:10.1016/S0140-6736(03)13802-2.
3. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al; HIV Outpatient Study (HOS) Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. *J Acquir Immune Defic Syndr*. 2006;43(1):27-34. doi:10.1097/01.qai.0000233317.46740.2d.
4. Bategay M, Nüesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. *Lancet Infect Dis*. 2006;6(5):280-7. doi:10.1016/S1473-3099(06)70463-7.
5. Yamashita TE, Phair JP, Muñoz A, Margolick JB, Detels R, O'Brien SJ, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. *AIDS*. 2001;15(6):735-46. doi:10.1097/00002030-200104120-00006.

6. Lokpo SY, Ofori-Attah PJ, Ameke LS, Obirikorang C, Orish VN, Kpene GE, et al. Viral suppression and its associated factors in HIV patients on highly active antiretroviral therapy (HAART): a retrospective study in the Ho Municipality, Ghana. *AIDS Res Treat*. 2020;2020:8898791. doi:10.1155/2020/8898791.
7. Lecher SL, Ellenberger D, Kim AA, Fonjungo PN, Agolory S, Borget MY, et al. Scale-up of HIV viral load monitoring—seven sub-Saharan African countries. *MMWR Morb Mortal Wkly Rep*. 2015;64(46):1287-90. doi:10.15585/mmwr.mm6446a4.
8. Hoffman J, van Johan G, Colebunders R, McKellar M. Role of the CD4 count in HIV management. *HIV Ther*. 2010;4(1):27-39. doi:10.2217/hiv.09.35.
9. The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. *PLoS Med*. 2012;9(3):e1001194. doi:10.1371/journal.pmed.1001194.
10. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. *AIDS*. 2008;22(7):841-8. doi:10.1097/QAD.0b013e3282f7e97d.
11. Loutfy MR, Walmsley SL, Mullin CM, Perez G, Neaton JD; Terry Beinr Community Programs for Clinical Research on AIDS (CPCRA); Canada HIV Trials Network. CD4+ cell count increase predicts clinical benefits in patients with advanced HIV disease and extensive pretreatment. *Clin Infect Dis*. 2008;46(11):1725-33. doi:10.1086/587866.
12. Grabar S, Moing VL, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. *Ann Intern Med*. 2000;133(6):401-10. doi:10.7326/0003-4819-133-6-200009190-00008.
13. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4 cell count and viral load response to antiretroviral therapy. *AIDS*. 2014;28(8):1193-202. doi:10.1097/QAD.000000000000163.
14. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. In: *HIV/AIDS Programme: strengthening health services to fight HIV/AIDS*. Geneva: World Health Organization; 2010. Available from: <https://www.who.int/publications/i/item/9789241599818>.
15. Takuva S, Maskew M, Brennan AT, Long L, Sanne I, Fox MP. Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. *J Int AIDS Soc*. 2014;17(1):18651. doi:10.7448/IAS.17.1.18651.
16. Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JSG. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. *AIDS*. 2006;20(3):371-7. doi:10.1097/01.aids.0000200532.80006.7e.
17. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. *Arch Intern Med*. 2003;163(18):2187-95. doi:10.1001/archinte.163.18.2187.
18. Nakanjako D, Kiragga A, Ibrahim F, Castelnovo B, Kanya MR, Easterbrook PJ. Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. *AIDS Res Ther*. 2008;5:23. doi:10.1186/1742-6405-5-23.
19. Yang X, Su B, Zhang X, Liu Y, Wu H, Zhang T. Incomplete immune reconstitution in HIV/AIDS patients on antiretroviral therapy: challenges of immunological non-responders. *J Leukoc Biol*. 2020;107(4):597-612. doi:10.1002/JLB.5MR0119-419R.
20. Nakanjako D, Kiragga AN, Musick BS, Yiannoutsos CT, Wools-Kaloustian K, Diero L, et al. Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa. *AIDS*. 2021;35(5):775-84. doi:10.1097/QAD.0000000000002794.
21. Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP, et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS- and non-AIDS diseases. *J Acquir Immune Defic Syndr*. 2008;48(5):541-6. doi:10.1097/QAI.0b013e31817bebb3 .
22. Lewden C, Chêne G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm³ on long-term combination antiretroviral therapy reach same mortality rates as the general population. *J Acquir Immune Defic Syndr*. 2007;46(1):72-7. doi:10.1097/QAI.0b013e3180d0f4f9.
23. Gutiérrez F, Padilla S, Masía M, Iribarren JA, Moreno S, Viciano P, et al. Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. *Curr HIV Res*. 2008;6(2):100-7. doi:10.2174/157016208784223779.
24. Boatman JA, Baker JV, Emery S, Furrer H, Mushatt DM, Sedlacek D, et al. Risk factors for low CD4+ count recovery despite viral suppression among participants initiating antiretroviral treatment with CD4+ counts >500 cells/mm³: findings from the Strategic Timing of AntiRetroviral Therapy (START) trial. *J Acquir Immune Defic Syndr*. 2019;81(1):10-7. doi:10.1097/QAI.0000000000001964.
25. Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D'Aquila RT, et al. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS Clinical Trials Group study. *J Infect Dis*. 2006;194(8):1098-107. doi:10.1086/507707.

26. Geng EH, Neilands TB, Thiebaut R, Bwana MB, Nash D, Moore RD, et al. CD4+ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. *Int J Epidemiol*. 2015;44(1):251-63. doi:10.1093/ije/dyu267.
27. Kesselring A, Gras L, Wit FW, Reiss P, de Wolf F. Maximum capacity of restoration of CD4 counts is lower in HIV-1-infected patients from Sub-Saharan Africa during the first months of cART: the Athena cohort. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston, MA. Abstract no. 794. DOI: N/A.
28. Kigozi IM, Dobkin LM, Martin JN, Geng EH, Muyindike W, Emenyonu NI, et al. Late disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-Saharan Africa. *J Acquir Immune Defic Syndr*. 2009;52(2):280-9. doi:10.1097/QAI.0b013e3181ab2d4f.
29. Belay GM, Endalamaw A, Ayele AD. Late presentation of HIV positive adults and its predictors to HIV/AIDS care in Ethiopia: a systematic review and meta-analysis. *BMC Infect Dis*. 2019;19(1):534.
30. Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayjian, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. *AIDS*. 2003; 17:2015–2023.
31. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. *J Virol*. 2003;77(11):11708–11717. doi:10.1128/JVI.77.21.11708-11717.2003
32. Schacker T. The role of secondary lymphatic tissue in immune deficiency of HIV infection. *AIDS*. 2008;22 Suppl 2:S13–S18. doi:10.1097/QAD.0b013e3282f9feef
33. Estes JD, Baker JV, Brenchley JM, Khoruts A, Barthold JL, Bantle A, et al. Collagen deposition limits immune reconstitution in the gut. *J Infect Dis*. 2008;198(4):456–464. doi:10.1086/590159
34. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. *AIDS*. 2003;17(12):1907–1915. doi:10.1097/00002030-200308150-00004
35. Smith K, Aga E, Bosch RJ, Valdez H, Connick E, Landay A, et al. Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. *AIDS*. 2004;18(15):1953–1956. doi:10.1097/00002030-200410150-00007
36. Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, et al. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of Lopinavir-Ritonavir treatment. *Clin Infect Dis*. 2007;44(5):749–754. doi:10.1086/511643
37. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. *Lancet*. 2007;370(9585):407–413. doi:10.1016/S0140-6736(07)61158-9
38. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. *Clin Infect Dis*. 2009;48(6):787–794. doi:10.1086/596891
39. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μl in HIV type 1-infected individuals receiving potent antiretroviral therapy. *Clin Infect Dis*. 2005;41(3):361–372. doi:10.1086/431352
40. Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, et al. CD4 cell counts of 800 cells/mm³ or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm³ or greater. *J Acquir Immune Defic Syndr*. 2007;45(2):183–192. doi:10.1097/QAI.0b013e318042e12a
41. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: WHO; 2016. doi:10.1016/S0140-6736(17)31710-2 (related update)
42. Frescura L, Godfrey-Faussett P, Alfaro-Magleña M, El-Sadr W, Syarif O, Ghys PD. Achieving the 95-95-95 targets for all: a pathway to ending AIDS. *PLoS One*. 2022;17(8):e0272405. doi:10.1371/journal.pone.0272405
43. UNAIDS. Fast-Track: accelerating action to end the AIDS epidemic by 2030 [Internet]. Geneva: UNAIDS; 2015 [cited 2026 Mar 29]. Available from: https://www.unaids.org/sites/default/files/media_asset/20151027_UpdateFastTrack_en.pdf
44. Lecher S, Ellenberger D, Kim AA, Fonjongo PN, Agolory S, Borget MY, et al. Scale-up of HIV viral load monitoring—seven sub-Saharan African countries, 2012-2016. *MMWR Morb Mortal Wkly Rep*. 2015;64(46):1287-90. doi:10.15585/mmwr.mm6446a3
45. Ghana AIDS Commission. Ghana may not meet the 90-90-90 target by 2020. Accra: Ghana AIDS Commission; 2019.
46. Ayisi-Boateng NK, Opoku DA, Nkrumah I, Frempong B, Owusu M, Oduro E, et al. Clinical profile and predictors of viral suppression in HIV-infected older adults at a university hospital in Kumasi, Ghana. *AIDS Care*. 2023;35(12):1821-9. doi:10.1080/09540121.2022.2119468

47. Sheth AN, Ofotokun I, Buchacz K, Armon C, Chmiel JS, Hart R, et al. Antiretroviral regimen durability and success in treatment-naïve and treatment-experienced patients by year of treatment initiation, United States, 1996-2011. *J Acquir Immune Defic Syndr*. 2016;71(1):47-56. doi:10.1097/QAI.0000000000000784
48. Kayigamba FR, Franke MF, Bakker MI, Rodriguez CA, Bagiruwigize E, Wit FW, et al. Discordant treatment responses to combination antiretroviral therapy in Rwanda: a prospective cohort study. *PLoS One*. 2016;11(7):e0159446. doi:10.1371/journal.pone.0159446
49. Gelba SB, Fikadu S, Legesse AK, Wubet H, Yesuf MA, Abera W, et al. Assessment of pattern of CD4+ T-cell recovery among human immunodeficiency virus patients after initiation of highly active antiretroviral therapy at Arsi Negelle Health Center, Ethiopia: a retrospective cross-sectional study. *HIV AIDS (Auckl)*. 2020;12:69-77. doi:10.2147/HIV.S235769
50. Asfaw A, Ali D, Eticha T, Alemayehu A, Alemayehu M, Kindeya F. CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, Northern Ethiopia: a retrospective cross-sectional study. *PLoS One*. 2015;10(3):e0122583. doi:10.1371/journal.pone.0122583
51. Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, et al. CD4 cell counts of 800 cells/mm³ or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm³ or greater. *J Acquir Immune Defic Syndr*. 2007;45(2):183-192. doi:10.1097/QAI.0b013e318042e12a
52. Desta AA, Woldearegay TW, Berhe AA, Futwi N, Gebru GG, Godefay H. Immunological recovery, failure and factors associated with CD-4 T-cells progression over time, among adolescents and adults living with HIV on Antiretroviral Therapy in Northern Ethiopia: A retrospective cross sectional study. *PLOS ONE*. 2019; 14(12):e0226293.
53. Mulu A, Liebert UG, Maier M. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. *BMC Infect Dis*. 2014;14:28. doi:10.1186/1471-2334-14-28
54. Anude CJ, Eze E, Onyegbutulem HC, Charurat M, Etiebet M-A, Ajayi S, et al. Immuno-virologic outcomes and immunovirologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. *BMC Infect Dis*. 2013;13:113. doi:10.1186/1471-2334-13-113
55. Kroeze S, Ondoa P, Kityo CM, Siwale M, Akanmu S, Wellington M, et al. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. *AIDS*. 2018;32(8):1043-1051. doi:10.1097/QAD.0000000000001789
56. Lawn SD, Myer L, Bekker L-G, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. *BMC Infect Dis*. 2006;6:59. doi:10.1186/1471-2334-6-59
57. Gezie LD. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis. *BMC Res Notes*. 2016;9:377. doi:10.1186/s13104-016-2177-0
58. Dronda F, Moreno S, Moreno A, Casado JL, Perez-Elias MJ, Antela A. Long-term outcomes among antiretroviral-naïve human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. *Clin Infect Dis*. 2002;35(9):1005-1009. doi:10.1086/342567
59. Torti C, Prosperi M, Motta D, Digambenedetto S, Maggiolo F, Paraninfo G, et al. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. *Clin Microbiol Infect*. 2012;18(5):449-458. doi:10.1111/j.1469-0691.2011.03691.x
60. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. *Clin Infect Dis*. 2007;44(3):441-446. doi:10.1086/510746
61. Roul H, Mary-Krause M, Ghosn J, Delaugerre C, Pialoux G, Cuzin L, et al. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. *AIDS*. 2018;32(17):2605-2614. doi:10.1097/QAD.0000000000001995
62. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. *Clin Infect Dis*. 2009;48(3):350-361. doi:10.1086/595888